MannKind Corporation 2012 Form 10-K Summary
Business context and reporting period
MannKind Corporation is a development-stage biopharmaceutical company focused primarily on AFREZZA, an ultra-rapid-acting inhaled insulin using its proprietary Technosphere delivery platform and Dreamboat inhaler. The filing covers the fiscal year ended December 31, 2012; the referenced fourth-quarter results are unaudited.
AFREZZA was not approved for marketing and MannKind had no commercial product or product sales. The company had 246 full-time employees at year-end and operated primarily in the United States.
Financial performance and key metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $35,000 | $50,000 | Down $15,000 |
| Research and development expense | $101.5 million | $100.0 million | Up 2% |
| General and administrative expense | $45.5 million | $40.6 million | Up 12% |
| Loss from operations | $147.0 million | $140.5 million | Higher loss |
| Net loss | $169.4 million | $160.8 million | Higher loss |
| Net loss per share | $0.94 | $1.32 | Lower loss per share due primarily to share issuance |
| Cash used in operations | $119.9 million | $123.8 million | Use decreased $4.0 million |
| Cash and cash equivalents at year-end | $61.8 million | $2.7 million | Up $59.2 million |
| Total assets | $251.3 million | $199.6 million | Up $51.8 million |
| Stockholders’ deficit | $110.7 million | $313.7 million | Deficit reduced by $203.0 million |
Revenue was immaterial relative to operating expenses, and the filing does not provide a meaningful operating or net margin. The company reported a cumulative net loss of approximately $2.1 billion and cumulative negative operating cash flow of approximately $1.6 billion since inception.
At December 31, 2012, senior convertible notes had a carrying value of $212.0 million, consisting of $115.0 million of 3.75% notes due December 2013 and $100.0 million of 5.75% notes due August 2015, before unamortized issuance costs. The related-party note payable to The Mann Group was $119.6 million, with $125.4 million available for future borrowing. Total contractual obligations were approximately $396.0 million, including debt, interest, purchase commitments and leases.
Material changes versus the prior comparable period
- Clinical research and development spending increased substantially as studies 171 and 175 progressed; clinical expense rose 90% to $47.9 million.
- Manufacturing expense declined 31% to $40.1 million, primarily because no additional insulin purchases were made after the 2011 supply-agreement settlement and inventory acquisition.
- General and administrative expense increased 12%, primarily because of a $6.5 million litigation settlement charge and higher stock-based compensation.
- Other expense was $1.2 million in 2012 versus $1.5 million of other income in 2011, primarily reflecting fair-value changes in related-party forward purchase contracts.
- Financing activities generated $179.6 million, principally from February and October equity-and-warrant offerings, compared with $63.4 million in 2011.
- The company issued substantial common stock and warrants and exchanged shares for cancellation of related-party debt. Shares outstanding increased from approximately 131.5 million at year-end 2011 to 286.0 million at year-end 2012, creating significant dilution.
- Fourth-quarter 2012 net loss was $51.8 million, compared with $36.4 million in the fourth quarter of 2011. Fourth-quarter loss per share was $0.23 in both periods because of the increase in weighted-average shares.
Guidance, outlook, commentary and risks
- MannKind expected to complete AFREZZA studies 171 and 175 in the second quarter of 2013 and submit the results as an amendment to its NDA during the fourth quarter of 2013. The filing cautions that the studies could fail to achieve statistical significance or satisfy FDA requirements.
- Management expected overall research and development expense and general and administrative expense to decrease in 2013 as clinical trials were completed and legal expenses declined.
- The company expected negative operating cash flow to continue until AFREZZA received regulatory approval and was commercialized. Management stated that existing resources, including available related-party borrowings, were expected to fund planned operations through at least the third quarter of 2013.
- The $115.0 million principal amount of 2013 notes was due in December 2013, and year-end cash was insufficient to repay it. The filing states that additional financing, refinancing, asset sales, licensing, or a strategic commercialization partnership would be required and raises substantial doubt about the company’s ability to continue as a going concern.
- MannKind had not entered into an AFREZZA commercialization partnership and had no sales or distribution capabilities. Commercial success would therefore depend on obtaining a partner or building those capabilities.
- AFREZZA remained subject to FDA approval as a drug-device combination product, including additional clinical, regulatory and manufacturing requirements. FDA approval, if obtained, could be delayed, restricted, or denied.
- Key risks include continued operating losses, insufficient liquidity, debt repayment and refinancing risk, dilution from equity offerings and convertible securities, clinical and regulatory failure, manufacturing and supply constraints, market acceptance and reimbursement uncertainty, competition, intellectual-property disputes, and product-liability exposure.
- The securities class action and shareholder derivative actions were settled in 2012. Insurers paid $16.0 million for the securities settlement and $800,000 for the derivative settlement; the company issued or agreed to issue approximately 3.0 million shares in aggregate and adopted specified governance measures.
- On March 18, 2013, the company entered into at-the-market sales agreements permitting aggregate sales of up to $50.0 million of common stock, subject to the stated agreement limitations. These agreements create additional potential dilution but did not require sales.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting, with an explanatory paragraph regarding substantial doubt about going-concern status.
Most important facts for investors to verify
- Current AFREZZA regulatory status, clinical-trial results, NDA resubmission timing and any subsequent FDA requests.
- Actual cash burn, liquidity and availability under the The Mann Group facility after the third quarter of 2013.
- Repayment, refinancing, conversion or restructuring of the $115.0 million 2013 notes and other debt maturities.
- Subsequent equity, warrant and ATM issuance activity, including dilution from approximately 128.3 million potentially dilutive securities outstanding at year-end 2012.
- Whether MannKind secured a development or commercialization partner and whether it established the required sales, marketing and distribution infrastructure.
- Commercial manufacturing readiness, FDA inspections, insulin supply availability and qualification of Dreamboat inhaler and cartridge suppliers.
- Subsequent changes in litigation, intellectual-property claims, product-liability exposure and going-concern disclosures.